The market size for synthetic stem cells is expected to grow from USD 14 million in 2023 to USD 37 million by 2028, at a CAGR of 22.5% during the forecast period. The ethical concerns on the use of embryonic stem cells and the risk of tumor formation and immune response to natural stem cells are the key factors driving the growth of this market.
The major applications of synthetic stem cells include cardiovascular diseases, neurological disorders, and other diseases that require regenerative therapy. Cardiovascular diseases have high prevalence across the globe. Currently, synthetic mesenchymal cells have been developed only for cardiac tissue and have been tested in mice models. The research on cardiac synthetic stem cells is expected to enter the clinical phase in the coming 2-3 years, and the first commercial product would be cardiac synthetic stem cells in the next five years.
North America is estimated to account for the largest share of the market in 2023. This is majorly attributed to the rising research on stem cells in the region, coupled with public-private funding. The region is a global leader in the research on regenerative therapies such as stem cells and is backed by funding on advanced research infrastructure to commercialize novel regenerative therapies. Moreover, North America is the pioneer of synthetic stem cell technology and will be the early adopter of this technology in the coming years.
The technology is developed and patented by North Carolina State University (NCSU) (US) and Zhengzhou University (China).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst